# Mindfulness for Cannabis Use Disorder: Check the Corrected Data > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/ced-mindfulness-for-cannabis-use-disord-2026-10-09/ > **Published:** 2026-10-09T22:44:06-04:00 | **Last Modified / Clinically Audited:** 2026-10-09T22:44:06-04:00 > **Clinical Summary:** medical cannabis research: Physician review of Corrigendum to "Brief mindfulness intervention for adults with cannabis use disorder: A randomised clinical tr... --- CED Clinical Relevance #88 Verified Clinical Evidence Primary literature analysis of Corrigendum to "Brief mindfulness intervention for adults with cannabis use disorder: A randomised clinical trial" [Drug Alcohol Depend. 277 (2025) 112909].. Clinical Insight | CED Clinic For adults with cannabis use disorder, a brief mindfulness intervention could offer a practical way to address craving and automatic use. Its clinical value depends on measurable changes in cannabis consumption, symptoms, functioning, and treatment retention. The supplied citation contains no results or correction text, so the direction and size of any treatment effect cannot be established. Clinicians should obtain the corrected article before describing this intervention as effective. Patients can still discuss mindfulness as a supportive skill within an individualized treatment plan, with clear goals and follow-up that assess whether daily life and cannabis-related problems improve. Clinical SciencePeer-ReviewedDosing ContextSafety SignalsPhysician Insight AudiencePatients, clinicians, healthcare providers, researchers, and policy analysts. Primary TopicClinical study review: Mindfulness for Cannabis Use Disorder: Check the C. Source[Read the full source](https://pubmed.ncbi.nlm.nih.gov/42692868/) Table of Contents - [Mindfulness for Cannabis Use Disorder: Check the Corrected Data](#Mindfulness_for_Cannabis_Use_Disorder_Check_the_Corrected_Data)[How to Interpret This Clinical Study](#How_to_Interpret_This_Clinical_Study)[Three Rules for Critical Reading](#Three_Rules_for_Critical_Reading) - [CED Perspective Lens: Eight Clinical Viewpoints](#CED_Perspective_Lens_Eight_Clinical_Viewpoints)[Clinical Evidence Synthesis](#Clinical_Evidence_Synthesis) - [Patient Communication](#Patient_Communication) - [Dosing & Formulations](#Dosing_Formulations) - [Safety & Side Effect Profile](#Safety_Side_Effect_Profile) - [Regulatory & Policy Dynamics](#Regulatory_Policy_Dynamics) - [Mechanisms & Physiology](#Mechanisms_Physiology) - [Research Limitations](#Research_Limitations) - [Future Outlook](#Future_Outlook) - [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related) # Mindfulness for Cannabis Use Disorder: Check the Corrected Data A correction linked to a randomized mindfulness trial deserves careful clinical review. The supplied citation identifies the intervention and population, but treatment effects, sample size, and the correction’s impact remain unverified. What This Study Teaches Us The supplied citation identifies a correction to a 2025 randomized trial of brief mindfulness for adults with cannabis use disorder. Sample size, numerical endpoints, treatment differences, and the corrected content are unavailable, so no specific efficacy or safety finding can be reported. Why This Matters Patients deserve accurate expectations before investing time in a behavioral treatment. The corrected outcomes are needed to judge whether this intervention offers meaningful benefit and whether the correction changes clinical advice. Study SnapshotPost TypePhysician-Guided Clinical Science Deep DivePrimary SourceDrug and alcohol dependencePublication Date2026Oct01Evidence LevelPublished ErratumFocus AreaMindfulness for Cannabis Use Disorder: Check the Corrected DLead AuthorsValentina Lorenzetti, Eugene McTavish, Hannah Thomson, Adam Clemente et al.DOI10.1016/j.drugalcdep.2026.113332PMIDPMID: 42692868 Clinical Bottom Line This study review translates complex data into practical clinical insights, maintaining realistic therapeutic expectations. Headline vs. Reality Truth Meter | Clinical Analysis **Mainstream Media Claim:** Hypothetical headline framing, not a verified news report: A brief mindfulness session treats cannabis addiction. **Primary Journal Data:** The supplied title identifies a corrigendum linked to a randomized trial in adults with cannabis use disorder. It supplies no sample size, comparator, endpoint results, confidence intervals, or description of what was corrected. **Dr. Caplan’s Clinical Verdict:** A treatment claim requires the corrected results and a clinically meaningful benefit over the comparator. Until those details are available, mindfulness can be discussed as a supportive option without promising that this particular intervention reduces cannabis use. Primary Analysis | Corrigendum to “Brief mindfulness interv **Study Overview:** Clinical evidence analysis. **Primary Source & Scope:** Published in *Drug and alcohol dependence* (2026Oct01) conducted by Valentina Lorenzetti, Eugene McTavish, Hannah Thomson, Adam Clemente et al.. [Primary Source Link](https://pubmed.ncbi.nlm.nih.gov/42692868/) | **Primary Record:** DOI: 10.1016/j.drugalcdep.2026.113332 | PMID: 42692868 How Strong Is This Evidence? The original title identifies randomized allocation, a design that can support causal conclusions when properly conducted. Sample size, allocation methods, comparator, endpoint definitions, attrition, and statistical estimates are unavailable in the supplied material. The strength and precision of the corrected findings therefore cannot be graded. Where This Paper Deserves Skepticism Without the amendment text, the effect of the correction on the study’s conclusions remains unknown. Expectation effects, unequal treatment attention, self-report error, and missing follow-up are relevant appraisal questions for a behavioral trial, but none can be confirmed as a flaw here. Selective outcome reporting also requires comparison with the registered analysis plan. What This Paper Does Not Show The supplied citation does not establish that brief mindfulness reduces cannabis consumption, produces remission, or improves functioning. It does not support cannabinoid dosing recommendations, comparative superiority over established treatments, or a change in regulatory requirements. How This Fits With the Broader Clinical Conversation Research on cannabis use disorder has examined motivational enhancement, cognitive behavioral approaches, contingency management, and other psychosocial interventions. Treatment selection depends on the person’s goals, comorbid conditions, available services, and ability to participate. A brief mindfulness approach belongs within this broader effort to make effective support practical and accessible. Brief treatments raise two separate questions: whether patients can engage with them and whether their effects last. Short-term changes in craving may be useful, but sustained improvements in use patterns and functioning carry greater clinical weight. The corrected trial results are needed to locate this intervention within that evidence. For patients using cannabis to manage medical symptoms, care must account for the condition that prompted use. A reduction plan may require alternative symptom treatment and withdrawal support. Behavioral skills can accompany that process without determining the appropriate cannabis formulation or dose. Editorial Commentary *A brief mindfulness intervention could be useful if it produces measurable improvement that patients can sustain. For cannabis use disorder, the relevant outcomes include control over use, fewer cannabis-related problems, better functioning, and acceptable treatment burden. No numerical outcome is available in the supplied material.* *The correction needs to be examined at the level of the actual amendment. Its clinical importance depends on whether it changes a treatment estimate, an outcome definition, or another detail that affects interpretation. Broad claims about successful treatment should wait for that verification.* *Patient care can continue through individualized assessment, collaborative goals, and established psychosocial approaches. Mindfulness may fit into that plan, with its value judged through the patient’s experience and measurable progress.* What a Careful Reader Should Take Away Obtain the correction and corrected trial results before making a treatment claim. Patients interested in mindfulness can discuss a monitored, goal-based role for it within comprehensive care. [https://cedclinic.com/ask](https://cedclinic.com/ask)Ask about this study:[🛡️Use Disorder](https://cedclinic.com/ask)[⚖️Dosing](https://cedclinic.com/ask)[🛡️Safety](https://cedclinic.com/ask)[🔎This study's limits](https://cedclinic.com/ask) Evidence Interpretation Guide ## How to Interpret This Clinical Study Navigating biomedical publications regarding Corrigendum to “Brief mindfulness interventio requires reviewing study methodology and patient eligibility. ### Three Rules for Critical Reading **Critical Rule**Identify the exact correction and determine whether it changes methods, numerical results, or conclusions. **Critical Rule**Check the prespecified primary endpoint, comparator, sample size, missing-data approach, treatment difference, and confidence interval. **Critical Rule**Separate craving changes from reduced cannabis use, remission, and functional improvement, then assess how long any benefit lasted. Key Evaluation Question Does the corrected analysis show a clinically meaningful benefit over the comparator, with sufficient precision and follow-up? The Patient Question Could mindfulness support my treatment goals, and which changes in cannabis use, symptoms, or functioning would we track? The Bottom Line The citation identifies a corrected randomized trial, but its clinical findings remain unverified because the results and amendment text were not supplied. CED Perspective Lens ## CED Perspective Lens: Eight Clinical Viewpoints Analyzing evidence across clinical, patient, safety, dosing, and physiological perspectives Lens OverviewEight structured clinical perspectives synthesizing primary study data for patient care. #### Clinical Evidence Synthesis The cited original article concerns a randomized trial of a brief mindfulness intervention for adults with cannabis use disorder. Random allocation can support causal inference when allocation procedures, comparison conditions, follow-up, and analysis are sound. The citation alone does not establish whether those safeguards were adequate. The corrected results need to specify participant numbers, the primary endpoint, treatment differences, and uncertainty around those differences. A decrease in craving, fewer cannabis-use days, and diagnostic remission carry different clinical meanings. The correction’s effect on those outcomes must be established before any estimate of benefit can be communicated. Lens takeawayClinical confidence depends on the corrected treatment comparison, its precision, and whether the measured benefit matters to patients. #### Patient Communication A patient considering mindfulness deserves a concrete explanation of the intended goal. Possible goals include noticing urges earlier, tolerating distress, and creating a pause before cannabis use. Those goals should be distinguished from demonstrated trial outcomes, which are unavailable in the supplied citation. Cannabis use disorder involves a pattern of use associated with impairment or distress. Frequency alone does not establish the diagnosis, and medically motivated use does not exclude it. A useful clinical conversation asks what cannabis helps, what difficulties it creates, and what the patient wants to change. Progress can be tracked through use patterns, functioning, sleep, craving, and personally meaningful goals. Lens takeawayDiscuss mindfulness through specific patient goals and measured progress, while keeping claims about this trial’s effectiveness provisional. #### Dosing & Formulations The supplied citation offers no basis for recommending a THC dose, CBD dose, product ratio, or route of administration. A behavioral intervention can address cannabis-related habits without identifying a preferred cannabinoid formulation. Product recommendations require separate evidence and an assessment of the patient’s symptoms, exposure, and risks. For patients using cannabis medically, a medication review can document product potency, estimated THC exposure, frequency, route, and reasons for use. Changes should be individualized, especially when cannabis is being used for persistent symptoms. Any reduction plan should include monitoring for withdrawal and symptom recurrence. These are general care considerations, not verified findings from the cited trial. Lens takeawayThis citation cannot guide cannabinoid dosing; product changes require a separate clinical assessment and an individualized follow-up plan. #### Safety & Side Effect Profile Safety assessment requires more than a general impression that mindfulness is gentle. Clinicians should ask whether practices worsen anxiety, evoke distress, or feel difficult for patients with trauma-related symptoms. The supplied citation provides no adverse-event counts, discontinuation rates, or information about how harms were monitored. Cannabis reduction can produce irritability, sleep disturbance, anxiety, and appetite changes in people with regular exposure. Those symptoms may need support even when the patient is using a behavioral technique. Severe mood symptoms, suicidal thoughts, psychosis, or inability to manage daily responsibilities warrant prompt clinical assessment. Mindfulness should fit within care that addresses these risks directly. Lens takeawayMonitor distress, withdrawal, and psychiatric symptoms during treatment, and use the corrected safety data when judging this intervention. #### Regulatory & Policy Dynamics The supplied citation establishes no change to prescribing rules, cannabis access, reimbursement, or professional practice requirements. Clinical adoption would depend on the corrected findings, the intervention’s demands, and the availability of practitioners who can deliver it consistently. Local coverage and referral options require separate confirmation. A brief intervention may be attractive where specialist addiction care is difficult to obtain. Its practical accessibility still depends on session length, training requirements, language, delivery format, and patient participation. Those details are absent here. Health services considering this approach should assess effectiveness and implementation costs before making it a routine pathway for adults with cannabis use disorder. Lens takeawayAccess decisions should reflect verified treatment benefit, delivery requirements, and local coverage, none of which are established here. #### Mechanisms & Physiology Mindfulness practices commonly aim to strengthen awareness of sensations, thoughts, and urges. For cannabis use disorder, a plausible behavioral target is the learned connection between discomfort, craving, and immediate use. Plausibility alone cannot establish that the intervention changed cannabis consumption or improved functioning. Claims about brain circuitry, stress hormones, or endocannabinoid signaling would require corresponding measurements. The supplied citation identifies none. The clinical question is whether participants developed skills that translated into sustained change outside the treatment session. That requires outcome data and follow-up. A proposed mechanism can help explain a result after it is established, but cannot substitute for a reliable treatment comparison. Lens takeawayMindfulness has plausible behavioral targets, but this citation supplies no verified physiological mechanism or evidence of sustained clinical change. #### Research Limitations The central uncertainty is the absence of the correction text and the original trial’s results. A correction could concern authorship, wording, a table, or an analysis. Its existence alone establishes neither a failure of the trial nor continued validity of its conclusions. Evaluation requires the corrected article, trial registration, participant flow, and analysis plan. Relevant questions include whether outcomes were prespecified, missing data differed between groups, and the comparator matched therapist attention. Self-reported cannabis use may also be affected by recall or expectations. None of these potential limitations can be attributed to this particular trial without its methods and results. Lens takeawayObtain the correction and trial methods before deciding whether the findings support a change in clinical practice. #### Future Outlook The next useful step is to determine exactly what changed and whether that change affects the treatment estimate or interpretation. If the correction alters results, clinicians need the revised group comparisons and uncertainty estimates. If it concerns administrative details, the original clinical findings still require independent appraisal. Future research on brief mindfulness interventions should measure cannabis exposure, disorder symptoms, functioning, and harms over meaningful follow-up periods. Comparisons with credible active treatments would help identify any added benefit. Studies should also describe intervention content and adherence clearly enough for clinicians to reproduce the treatment. These priorities follow from the clinical question, not from verified deficiencies in this trial. Lens takeawayThe corrected findings should determine the next clinical discussion, while longer follow-up and reproducible treatment descriptions support future adoption. Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](http://CEDclinic.com/book) [Cannabis Care](http://CEDclinic.com/book) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Share this Evidence Watch [X](https://twitter.com/intent/tweet?text=Mindfulness+for+Cannabis+Use+Disorder%3A+Check+the+Corrected+Data&url=https%3A%2F%2Fcedclinic.com%2Fced-mindfulness-for-cannabis-use-disord-2026-10-09%2F) [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fced-mindfulness-for-cannabis-use-disord-2026-10-09%2F) [BlueSky](https://bsky.app/intent/compose?text=Mindfulness+for+Cannabis+Use+Disorder%3A+Check+the+Corrected+Data%20https%3A%2F%2Fcedclinic.com%2Fced-mindfulness-for-cannabis-use-disord-2026-10-09%2F) [Instagram](https://www.instagram.com/drcaplan/) [Substack](https://doctorapprovedcannabis.substack.com/) [RSS](https://cedclinic.com/feed/) Source: [Primary Source: Corrigendum to "Brief mindfulness intervention for adults with cannabis use disorder: A randomised clinical trial" [Drug Alcohol Depend. 277 (2025) 112909].](https://pubmed.ncbi.nlm.nih.gov/42692868/) Related Reading at CED ClinicContinue exploring the evidence[Cannabis Use Disorder Is Rising Among US Adults](https://cedclinic.com/cannabis-use-disorder-rising-us-adults-2026/) More on this topic: Epidemiological evaluation of diagnostic trends, screening tools, and evidence-based patient counseling. [More on this topic: CUD trends & screening](https://cedclinic.com/cannabis-use-disorder-rising-us-adults-2026/)[PP-01 for Cannabis Withdrawal: What a 14-Person Trial Found](https://cedclinic.com/pp01-cannabis-withdrawal-proof-of-concept/) More on this topic: Clinical trial data evaluating pharmacological interventions and supportive care for cannabis withdrawal. [More on this topic: Withdrawal management](https://cedclinic.com/pp01-cannabis-withdrawal-proof-of-concept/)[Pancreatic Cancer Cannabis Trial Finds Modest THC Dose Signals for Anxiety and Sleep](https://cedclinic.com/ced-pancreatic-cancer-cannabis-trial-fi-2026-09-22/) More on this topic: Physician appraisal of adjunctive cannabinoid therapies in oncology, symptom management, and anxiety. [More on this topic: Cannabinoids in oncology](https://cedclinic.com/ced-pancreatic-cancer-cannabis-trial-fi-2026-09-22/) ## Frequently Asked Questions What can be established from the supplied citation? It identifies a corrigendum linked to a randomized trial of a brief mindfulness intervention for adults with cannabis use disorder. The original article is cited as Drug and Alcohol Dependence, volume 277, article 112909, published in 2025. Numerical results and the correction’s contents were not supplied. Does the correction mean the trial’s results are wrong? That cannot be determined from the title. Corrections can address administrative details or substantive results. The exact amendment must be reviewed before assessing its effect on the conclusions. Did mindfulness reduce cannabis use in this trial? The supplied material contains no treatment results. A reliable answer requires the corrected cannabis-use outcomes, comparison-group results, follow-up duration, and uncertainty estimates. How many people participated? The sample size is not provided. Both the number randomized and the number included in each outcome analysis are needed to assess precision and possible attrition bias. What is cannabis use disorder? It is a pattern of cannabis use associated with clinically significant impairment or distress. Assessment considers symptoms such as difficulty controlling use, continued use despite problems, and disruption of responsibilities. Frequent use alone does not establish the diagnosis. Can someone using cannabis for medical symptoms develop cannabis use disorder? Yes. Medical intent and problematic use can coexist. Assessment should consider therapeutic benefit, loss of control, adverse effects, and functioning without assuming that every regular medical user has a disorder. Can mindfulness be included in a treatment plan? It can be discussed as a supportive skill when it fits the patient’s preferences and needs. Expectations should remain realistic, and follow-up should assess actual benefit. This citation does not establish the effectiveness of the specific intervention. Does this research identify a safer THC-to-CBD ratio? No formulation results were supplied. This citation cannot support a particular THC-to-CBD ratio, cannabinoid dose, or route of administration. What should patients monitor when reducing cannabis? Track sleep, irritability, anxiety, appetite, craving, and the symptoms cannabis was being used to manage. Patients with severe psychiatric symptoms or substantial difficulty functioning should seek prompt clinical assessment. What information would make the findings clinically useful? The corrected primary outcome, absolute treatment difference, confidence interval, sample size, comparator, adverse events, and follow-up duration are central. Clinicians also need enough detail about the intervention to deliver it consistently. ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).